Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2018—NeuMoDx Molecular announced it has received FDA 510(k) clearance for its NeuMoDx 288 Molecular System and NeuMoDx GBS Assay. The fully automated NeuMoDx 288 is a scalable platform that integrates the diagnostic process, from extraction to detection, in approximately one hour. The analyzer can load up to 288 patient samples in a continuous random-access mode and features a walkaway time of more than six hours.
August 2018—Binding Site’s Immunologicals Group has added infectious and contagious disease state sera and plasma products to its line of products. The human-based serum/plasma biological materials cover a variety of infectious and contagious disease state conditions, including Epstein-Barr virus, influenza, measles, mumps, TORCH, and West Nile. Evaluation samples are available and all materials come in bulk formats for use in the manufacturing of calibration and quality control materials. The company offers comprehensive data on analyte positives and negatives along with a certificate of analysis. In a separate release, the Immunologicals Group announced it has expanded its antibody and antigen product offerings for human coagulation and complement applications.
August 2018—Aquaro Histology announced the launch of the Aquaro Wishbone blade-handling tool. The handheld tool allows histologists to remove and dispose of blades, as well as insert and align them, without having to touch the blade.
August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.
August 2018—Luxembourg-based Advanced Biological Laboratories has signed a definitive agreement to acquire CDL Pharma. CDL Pharma, headquartered in France, provides biological sample management solutions in clinical research for pharmaceutical laboratories, contact research organizations, biotechnology companies, and others.
August 2018—Hologic has obtained approval from Health Canada for its Panther Fusion system and Panther Fusion assays for respiratory virus infections. The Panther Fusion module adds the capacity to run PCR assays in addition to tests based on transcription-mediated amplification, the proprietary Hologic chemistry that powers the company’s Aptima brand.
August 2018—Qiagen launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents to enable accurate microbial community profiling from complex microbiome samples. The UCP Multiplex PCR Kit is a standalone product as well as a component of the QIAseq 16S/ITS Panels.
August 2018—Ortho Clinical Diagnostics received the CE mark for the Ortho Vitros XT 7600 integrated chemistry system. The digital chemistry is based on three technologies: dry slide, microslide, and digital imaging. Dry slide technology does not require water to run, which eliminates the risk of poor water quality affecting test results.
August 2018—Agena Bioscience has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics, an independent medical laboratories provider headquartered in Hangzhou, China.
August 2018—Array BioPharma announced that the FDA has approved Braftovi (encorafenib) capsules in combination with Mektovi (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation, as detected by an FDA-approved test.
